BioTricity Reports Unregistered Equity Sales
Ticker: BTCY · Form: 8-K · Filed: May 21, 2024 · CIK: 1630113
Sentiment: neutral
Topics: equity-sale, unregistered-securities, dilution
Related Tickers: BTCY
TL;DR
BioTricity sold unregistered equity, expect dilution.
AI Summary
BioTricity Inc. filed an 8-K on May 21, 2024, reporting on unregistered sales of equity securities and other events. The filing indicates that on May 15, 2024, the company entered into a securities purchase agreement for the sale of its common stock.
Why It Matters
This filing signals potential dilution for existing shareholders due to the issuance of new equity, which could impact the stock price.
Risk Assessment
Risk Level: medium — Unregistered equity sales can lead to dilution and signal potential financial distress or a need for capital.
Key Players & Entities
- BIOTRICITY INC. (company) — Registrant
- May 15, 2024 (date) — Date of earliest event reported
- May 21, 2024 (date) — Filing date
- Nevada (jurisdiction) — State of Incorporation
- 203 Redwood Shores Parkway, Suite 600 Redwood City, California 94065 (address) — Principal Executive Offices
FAQ
What type of securities were sold in the unregistered offering?
The filing states that common stock was sold, but does not specify the exact terms or price per share in this section.
Who were the purchasers in the unregistered sale?
The filing does not disclose the identity of the purchasers in this section, only that it was an unregistered sale of equity securities.
What is the purpose of this unregistered equity sale?
The filing does not explicitly state the purpose of the unregistered equity sale, but it is filed under 'Unregistered Sales of Equity Securities'.
When did the securities purchase agreement take effect?
The earliest event reported is May 15, 2024, which is when the company entered into the securities purchase agreement.
Is this a material event for BioTricity Inc.?
Yes, the filing is an 8-K, which is used to report material events that are of interest to investors.
Filing Stats: 1,489 words · 6 min read · ~5 pages · Grade level 14.1 · Accepted 2024-05-21 17:00:15
Key Financial Figures
- $0.001 B — ch registered Common Stock, Par Value $0.001 BTCY Nasdaq Capital Market Indicate
- $0.001 — s Series B Convertible Preferred Stock, $0.001 par value (the "Series B Preferred Stoc
- $9,090.91 — eferred Stock"), at a purchase price of $9,090.91 per share of Series B Convertible Prefe
- $1,000,000 — Preferred Stock, for gross proceeds of $1,000,000, with an option, at any time prior to t
- $354,545 — B Preferred Stock for gross proceeds of $354,545. On May 15, 2024, pursuant to the Purch
- $645,455 — B Preferred Stock for gross proceeds of $645,455. A copy of the side letter is filed as
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 28KB
- 0001493152-24-020909.txt ( ) — 251KB
- btcy-20240515.xsd (EX-101.SCH) — 3KB
- btcy-20240515_lab.xml (EX-101.LAB) — 33KB
- btcy-20240515_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: May 21, 2024 BIOTRICITY INC. By: /s/ Waqaas Al-Siddiq Waqaas Al-Siddiq Chief Executive Officer